NCT03952559 A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03945760 Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects Status COMPLETED Phase EARLY_PHASE1
NCT03915964 A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis Status COMPLETED Phase PHASE4
NCT03899259 A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata Status COMPLETED Phase PHASE3
NCT03843125 A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) Status TERMINATED Phase PHASE3
NCT03773978 A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis Status COMPLETED Phase PHASE3
NCT03773965 A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis Status RECRUITING Phase PHASE3
NCT03742973 A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA Status TERMINATED Phase PHASE2
NCT03733301 A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis Status COMPLETED Phase PHASE3
NCT03616964 A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II) Status COMPLETED Phase PHASE3
NCT03616912 A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus Status TERMINATED Phase PHASE3
NCT03570749 A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Status COMPLETED Phase PHASE2/PHASE3
NCT03559270 A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis Status TERMINATED Phase PHASE3
NCT03435081 A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis Status COMPLETED Phase PHASE3
NCT03428100 A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable Status COMPLETED Phase PHASE3
NCT03414502 Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response Status RECRUITING Phase PHASE3
NCT03334435 A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis Status COMPLETED Phase PHASE3